{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T05:50:31Z","timestamp":1787637031913,"version":"build-2736575974"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T00:00:00Z","timestamp":1696636800000},"content-version":"am","delay-in-days":279,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01NS117209"],"award-info":[{"award-number":["U01NS117209"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U01NS117278"],"award-info":[{"award-number":["U01NS117278"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.expneurol.2022.114240","type":"journal-article","created":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T02:02:05Z","timestamp":1665108125000},"page":"114240","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures"],"prefix":"10.1016","volume":"359","author":[{"given":"Doodipala Samba","family":"Reddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert H.","family":"Mbilinyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreevidhya","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2022.114240_bib562","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0028-3908(84)90227-2","article-title":"A pharmacological study in the kindling model of epilepsy","volume":"23","author":"Albertson","year":"1984","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0010","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1021\/acschemneuro.0c00677","article-title":"Cannabichromene, related phytocannabinoids, and 5-fluoro-cannabichromene have anticonvulsant properties in a mouse model of Dravet Syndrome","volume":"12","author":"Anderson","year":"2021","journal-title":"ACS Chem. Neurosci."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114240_bb0015","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1097\/j.pain.0000000000002463","article-title":"Sex differences in medical cannabis-related adverse effects","volume":"163","author":"Aviram","year":"2022","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11920-017-0775-9","article-title":"Cannabis, cannabinoids, and sleep: a review of the literature","volume":"19","author":"Babson","year":"2017","journal-title":"Curr. Psychiatry Rep."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bib567","doi-asserted-by":"crossref","first-page":"731","DOI":"10.2147\/NDT.S833","article-title":"Tiagabine: efficacy and safety in partial seizures - current status.","volume":"4","author":"Bauer","year":"2008","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.expneurol.2022.114240_bb0040","first-page":"1035","article-title":"Cannabinoids and terpenes: how production of photo-protectants can be manipulated to enhance Cannabis sativa L","volume":"12","author":"Brousseau","year":"2021","journal-title":"Phytochem. Front. Plant Sci."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-020-00024-2","article-title":"Cannabinoids for fibromyalgia pain: a critical review of recent studies (2015\u20132019)","volume":"2","author":"Cameron","year":"2020","journal-title":"J. Cannabis Res."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bib565","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/s00213-013-3276-5","article-title":"Neurosteroid interactions with synaptic and extrasynaptic GABA(A) receptors: regulation of subunit plasticity, phasic and tonic inhibition, and neuronal network excitability.","volume":"230","author":"Carver","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.expneurol.2022.114240_bb0050","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/j.1528-1167.2005.51204.x","article-title":"Gender differences in epilepsy","volume":"46","author":"Christensen","year":"2005","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bb0055","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1124\/pr.119.017392","article-title":"Sex differences in the epilepsies and associated comorbidities: implications for use and development of pharmacotherapies","volume":"72","author":"Christian","year":"2020","journal-title":"Pharmacol. Rev."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0060","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.117.246660","article-title":"3\u03b2-methyl-neurosteroid analogs are preferential positive allosteric modulators and direct activators of extrasynaptic \u03b4-subunit \u03b3-aminobutyric acid type A receptors in the hippocampus dentate gyrus subfield","volume":"365","author":"Chuang","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0065","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1124\/jpet.119.261735","article-title":"Isobolographic analysis of antiseizure activity of the GABA type A receptor-modulating synthetic neurosteroids brexanolone and ganaxolone with tiagabine and midazolam","volume":"372","author":"Chuang","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114240_bb0070","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.bbadis.2017.02.003","article-title":"Novel therapeutic approaches for disease-modification of epileptogenesis for curing epilepsy","volume":"1863","author":"Clossen","year":"2017","journal-title":"Biochim. Biophys. Acta Mol. basis Dis."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41582-019-0284-z","article-title":"Cannabinoids and the expanded endocannabinoid system in neurological disorders","volume":"16","author":"Cristino","year":"2020","journal-title":"Nat. Rev. Neurol."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114240_bb0090","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.682","article-title":"Diversity of molecular targets and signaling pathways for CBD","volume":"8","author":"de Almeida","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"issue":"10","key":"10.1016\/j.expneurol.2022.114240_bb0100","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S1474-4422(16)30158-2","article-title":"Sudden unexpected death in epilepsy: epidemiology, mechanisms, and prevention","volume":"15","author":"Devinsky","year":"2016","journal-title":"Lancet Neurol."},{"issue":"21","key":"10.1016\/j.expneurol.2022.114240_bb0105","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","article-title":"Trial of Cannabidiol for drug-resistant seizures in the Dravet Syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"20","key":"10.1016\/j.expneurol.2022.114240_bb0110","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0115","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia."},{"issue":"9","key":"10.1016\/j.expneurol.2022.114240_bb0130","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1111\/epi.16973","article-title":"Antiseizure effects of the cannabinoids in the amygdala-kindling model","volume":"62","author":"Fallah","year":"2021","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bb0135","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"02","key":"10.1016\/j.expneurol.2022.114240_bb0140","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4236\/pp.2015.62010","article-title":"Overcoming the bell-shaped dose-response of cannabidiol by using cannabis extract enriched in cannabidiol","volume":"06","author":"Gallily","year":"2015","journal-title":"Pharmacol. Pharm."},{"key":"10.1016\/j.expneurol.2022.114240_bib563","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/epi.13060","article-title":"Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy","volume":"56","author":"Geffrey","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114240_bib561","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0014-4886(69)90128-9","article-title":"A permanent change in brain function resulting from daily electrical stimulation.","volume":"25","author":"Goddard","year":"1969","journal-title":"Exp Neurol"},{"key":"10.1016\/j.expneurol.2022.114240_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106525","article-title":"Cannabidiolic acid exhibits entourage-like improvements of anticonvulsant activity in an acute rat model of seizures","volume":"169","author":"Goerl","year":"2021","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2022.114240_bb0160","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-3-030-57369-0_7","article-title":"Cannabidiol therapy for refractory epilepsy and seizure disorders","volume":"1264","author":"Golub","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2021.113946","article-title":"Contusion brain damage in mice for modelling of post-traumatic epilepsy with contralateral hippocampus sclerosis: comprehensive and longitudinal characterization of spontaneous seizures, neuropathology, and neuropsychiatric comorbidities","volume":"348","author":"Golub","year":"2022","journal-title":"Exp. Neurol."},{"issue":"S1","key":"10.1016\/j.expneurol.2022.114240_bb0175","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0180","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1089\/can.2019.0028","article-title":"Anticonvulsive properties of cannabidiol in a model of generalized seizure are transient receptor potential vanilloid 1 dependent","volume":"5","author":"Gray","year":"2020","journal-title":"Cannabis Cannabinoid Res."},{"key":"10.1016\/j.expneurol.2022.114240_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5402\/2012\/802649","article-title":"Evaluation of the effects of Sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: A model of multiple sclerosis","volume":"2012","author":"Hilliard","year":"2012","journal-title":"ISRN Neurol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0200","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.seizure.2012.03.001","article-title":"Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures","volume":"21","author":"Jones","year":"2012","journal-title":"Seizure"},{"issue":"42","key":"10.1016\/j.expneurol.2022.114240_bb0205","doi-asserted-by":"crossref","first-page":"11229","DOI":"10.1073\/pnas.1711351114","article-title":"Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome","volume":"114","author":"Kaplan","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114240_bb0210","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11064-017-2287-8","article-title":"Evaluation of cannabidiol in animal seizure models by the Epilepsy Therapy Screening Program (ETSP)","volume":"42","author":"Klein","year":"2017","journal-title":"Neurochem. Res."},{"issue":"20","key":"10.1016\/j.expneurol.2022.114240_bb0215","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","article-title":"Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor","volume":"172","author":"Laprairie","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108156","article-title":"Cannabidiol anticonvulsant effect is mediated by the PI3K\u03b3 pathway","volume":"176","author":"Lima","year":"2020","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0225","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1590\/1516-4446-2017-0015","article-title":"Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test","volume":"41","author":"Linares","year":"2018","journal-title":"Braz. J. Psychiatry"},{"key":"10.1016\/j.expneurol.2022.114240_bb0230","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.04.011","article-title":"The holy grail of epilepsy prevention: preclinical approaches to antiepileptogenic treatments","volume":"167","author":"L\u00f6scher","year":"2020","journal-title":"Neuropharmacology"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0245","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0301-0082(80)90006-4","article-title":"The kindling model of epilepsy: a review","volume":"15","author":"McNamara","year":"1980","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0260","series-title":"Sativex in Resistant Multiple Sclerosis Spasticity: Discontinuation Study in a Large Population of Italian Patients (SA.FE. Study)","author":"Messina","year":"2017"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0270","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.beem.2008.09.003","article-title":"Central side-effects of therapies based on CB1 cannabinoid receptor agonists and antagonists: focus on anxiety and depression","volume":"23","author":"Moreira","year":"2009","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114240_bib564","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects.","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.expneurol.2022.114240_bb0275","series-title":"Marijuana: A Reference Handbook - David E. Newton","author":"Newton","year":"2013"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0280","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1124\/jpet.113.203331","article-title":"Synergistic GABA-enhancing therapy against seizures in a mouse model of Dravet syndrome","volume":"345","author":"Oakley","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0285","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/epi.14629","article-title":"Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models","volume":"60","author":"Patra","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114240_bb0290","series-title":"J Neurol Neurosurg Psychiatry","first-page":"944","article-title":"Efficacy and Safety of Cannabinoid Oromucosal Spray for Multiple Sclerosis Spasticity","volume":"87","author":"Patti","year":"2016"},{"key":"10.1016\/j.expneurol.2022.114240_bb0295","series-title":"Paxinos and Franklin\u2019s the Mouse Brain in Stereotaxic Coordinates","author":"Paxinos","year":"1997"},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0305","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","article-title":"The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: \u03949-tetrahydrocannabinol, cannabidiol and \u03949-tetrahydrocannabivarin","volume":"153","author":"Pertwee","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114240_bb0310","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.nbd.2014.05.011","article-title":"Gender issues in antiepileptic drug treatment","volume":"72","author":"Perucca","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0315","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0013-4694(72)90177-0","article-title":"Modification of seizure activity by electrical stimulation: II. Motor seizure","volume":"32","author":"Racine","year":"1972","journal-title":"Electroencephalogr. Clin. Neurophysiol."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bb0320","doi-asserted-by":"crossref","first-page":"679","DOI":"10.5664\/jcsm.7070","article-title":"Medical cannabis and the treatment of obstructive sleep apnea: an American Academy of Sleep Medicine position statement","volume":"14","author":"Ramar","year":"2018","journal-title":"J. Clin. Sleep Med."},{"issue":"C","key":"10.1016\/j.expneurol.2022.114240_bb0325","first-page":"113","article-title":"Neurosteroids. Endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"C","key":"10.1016\/j.expneurol.2022.114240_bb0330","first-page":"113","article-title":"Neurosteroids: endogenous role in the human brain and therapeutic potentials","volume":"186","author":"Reddy","year":"2010","journal-title":"Prog. Brain Res."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0335","first-page":"2305","article-title":"Clinical pharmacology of current antiepileptic drugs","volume":"7","author":"Reddy","year":"2014","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2014.06.010","article-title":"Neurosteroids and their role in sex-specific epilepsies","volume":"72","author":"Reddy","year":"2014","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0345","first-page":"129","article-title":"The utility of cannabidiol in the treatment of refractory epilepsy","volume":"17","author":"Reddy","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.expneurol.2022.114240_bb0350","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/jnr.23853","article-title":"Sex differences in the anticonvulsant neurosteroids","volume":"95","author":"Reddy","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114240_bb0355","first-page":"5165","article-title":"Clinical pharmacology and therapeutics of antiepileptic drugs for epilepsy and seizure disorders","volume":"13","author":"Reddy","year":"2020","journal-title":"Int. J. Pharm. Sci. Nanotechnol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0360","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/B978-0-444-64123-6.00016-3","article-title":"Brain structural and neuroendocrine basis of sex differences in epilepsy","volume":"175","author":"Reddy","year":"2020","journal-title":"Handb. Clin. Neurol."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0365","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13028","article-title":"Neurosteroid replacement therapy for catamenial epilepsy, post-partum depression, and neuroendocrine disorders in women","volume":"34","author":"Reddy","year":"2021","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0370","first-page":"22646","article-title":"Therapeutic and clinical foundations of cannabidiol therapy for difficult-to-treat seizures in children and adults with refractory epilepsies","volume":"358","author":"Reddy","year":"2022","journal-title":"Exp. Neurol."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0375","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.115.230151","article-title":"The pharmacological basis of cannabis therapy for epilepsy","volume":"357","author":"Reddy","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114240_bb0380","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1124\/jpet.110.169854","article-title":"The testosterone-derived neurosteroid androstanediol is a positive allosteric modulator of GABAA receptors","volume":"334","author":"Reddy","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.expneurol.2022.114240_bb0385","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1523\/JNEUROSCI.4488-10.2011","article-title":"Development and persistence of limbic epileptogenesis are impaired in mice lacking progesterone receptors","volume":"31","author":"Reddy","year":"2011","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0390","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.yebeh.2012.05.024","article-title":"Finasteride inhibits the disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis","volume":"25","author":"Reddy","year":"2012","journal-title":"Epilepsy & Behav."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0395","doi-asserted-by":"crossref","DOI":"10.1016\/S0022-3565(24)39152-9","article-title":"Enhanced anticonvulsant activity of ganaxolone after neurosteroid withdrawal in a rat model of catamenial epilepsy","volume":"294","author":"Reddy","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2\u20133","key":"10.1016\/j.expneurol.2022.114240_bb0405","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.eplepsyres.2010.01.009","article-title":"Ganaxolone suppression of behavioral and electrographic seizures in the mouse amygdala kindling model","volume":"89","author":"Reddy","year":"2010","journal-title":"Epilepsy Res."},{"issue":"7","key":"10.1016\/j.expneurol.2022.114240_bib566","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.tips.2016.04.003","article-title":"Clinical Potential of Neurosteroids for CNS Disorders.","volume":"37","author":"Reddy","year":"2016","journal-title":"Trends Pharmacol Sci."},{"issue":"7\u20138","key":"10.1016\/j.expneurol.2022.114240_bb0410","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.neuropharm.2010.08.017","article-title":"Disease-modifying activity of progesterone in the hippocampus kindling model of epileptogenesis","volume":"59","author":"Reddy","year":"2010","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0415","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1124\/jpet.114.222075","article-title":"Antiseizure activity of midazolam in mice lacking \u03b4-subunit extrasynaptic GABA(A) receptors","volume":"353","author":"Reddy","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0420","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1124\/jpet.117.244939","article-title":"Epigenetic histone deacetylation inhibition prevents the development and persistence of temporal lobe epilepsy","volume":"364","author":"Reddy","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"4","key":"10.1016\/j.expneurol.2022.114240_bb0425","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1111\/epi.14693","article-title":"Extrasynaptic \u03b3-aminobutyric acid type A receptor-mediated sex differences in the antiseizure activity of neurosteroids in status epilepticus and complex partial seizures","volume":"60","author":"Reddy","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.expneurol.2022.114240_bb0430","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2021.135753","article-title":"Molecular mechanisms of sex differences in epilepsy and seizure susceptibility in chemical, genetic and acquired epileptogenesis","volume":"750","author":"Reddy","year":"2021","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.expneurol.2022.114240_bb0435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/7854_2020_191","article-title":"Does stress trigger seizures? Evidence from experimental models","volume":"55","author":"Reddy","year":"2022","journal-title":"Curr. Top. Behav. Neurosci."},{"issue":"6","key":"10.1016\/j.expneurol.2022.114240_bb0440","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1126\/sciadv.aaw1391","article-title":"The origins of cannabis smoking: chemical residue evidence from the first millennium BCE in the Pamirs","volume":"5","author":"Ren","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.expneurol.2022.114240_bb0445","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1600-0404.2008.01004.x","article-title":"Benzodiazepines in epilepsy: pharmacology and pharmacokinetics","volume":"118","author":"Riss","year":"2008","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.expneurol.2022.114240_bb0450","article-title":"Evaluation of sex differences in the potential of \u03949-tetrahydrocannabinol, cannabidiol, cannabidiolic acid, and oleoyl alanine to reduce nausea-induced conditioned gaping reactions in Sprague-Dawley rats","author":"Rock","year":"2022","journal-title":"Cannabis Cannabinoid Res."},{"issue":"Pt B","key":"10.1016\/j.expneurol.2022.114240_bb0455","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.yebeh.2016.11.006","article-title":"Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection","volume":"70","author":"Rosenberg","year":"2017","journal-title":"Epilepsy Behav."},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0460","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S1928","article-title":"Cannabinoids in the management of difficult to treat pain","volume":"4","author":"Russo","year":"2008","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.expneurol.2022.114240_bb0465","series-title":"Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential","author":"Russo","year":"2013"},{"issue":"21","key":"10.1016\/j.expneurol.2022.114240_bb0480","doi-asserted-by":"crossref","first-page":"5186","DOI":"10.3390\/molecules25215186","article-title":"Molecular targets of cannabidiol in experimental models of neurological disease","volume":"25","author":"Silvestro","year":"2020","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0485","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/hipo.450040305","article-title":"Long-term structural and functional alterations induced in the hippocampus by kindling: implications for memory dysfunction and the development of epilepsy","volume":"4","author":"Sutula","year":"1994","journal-title":"Hippocampus"},{"issue":"1","key":"10.1016\/j.expneurol.2022.114240_bb0490","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42238-021-00062-4","article-title":"The biosynthesis of the cannabinoids","volume":"3","author":"Tahir","year":"2021","journal-title":"J. Cannabis Res."},{"key":"10.1016\/j.expneurol.2022.114240_bb0495","first-page":"22591","article-title":"Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: a systematic review and meta-analysis","volume":"358","author":"Talwar","year":"2022","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.expneurol.2022.114240_bb0500","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1001\/jamaneurol.2020.4607","article-title":"Add-on cannabidiol treatment for drug-resistant seizures in tuberous sclerosis complex: a placebo-controlled randomized clinical trial","volume":"78","author":"Thiele","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.expneurol.2022.114240_bb0505","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0707133","article-title":"Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro","volume":"150","author":"Thomas","year":"2007","journal-title":"Br. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.expneurol.2022.114240_bb0515","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1007\/s12035-018-0898-y","article-title":"Prospects of cannabidiol for easing status epilepticus-induced epileptogenesis and related comorbidities","volume":"55","author":"Upadhya","year":"2018","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.expneurol.2022.114240_bb0520","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2017.07.014","article-title":"Anticonvulsant effect of cannabidiol in the pentylenetetrazole model: pharmacological mechanisms, electroencephalographic profile, and brain cytokine levels","volume":"75","author":"Vilela","year":"2017","journal-title":"Epilepsy & Behav."},{"issue":"4 Suppl 1","key":"10.1016\/j.expneurol.2022.114240_bb0525","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5698\/1535-7597.18.4s1.1","article-title":"Summary of antiepileptic drugs available in the United States of America: working toward a world without epilepsy","volume":"18","author":"Vossler","year":"2018","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.expneurol.2022.114240_bb0535","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.103.051920","article-title":"The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy","volume":"307","author":"Wallace","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114240_bb0540","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1109\/TAU.1967.1161901","article-title":"The use of fast Fourier transform for the estimation of power spectra: a method based on time averaging over short, modified periodograms","volume":"15","author":"Welch","year":"1967","journal-title":"IEEE Trans. Audio Electroacoust."},{"key":"10.1016\/j.expneurol.2022.114240_bb0545","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1124\/jpet.113.203653","article-title":"Estrous cycle regulation of extrasynaptic delta-containing GABA-A receptor plasticity and tonic inhibition in the hippocampus subfields","volume":"346","author":"Wu","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.expneurol.2022.114240_bb0560","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3389\/fphar.2017.00259","article-title":"Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life","volume":"8","author":"Zuardi","year":"2017","journal-title":"Front. Pharmacol."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622002655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014488622002655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:57:33Z","timestamp":1762149453000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014488622002655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":92,"alternative-id":["S0014488622002655"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114240","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of the FDA-approved cannabidiol on the development and persistence of temporal lobe epilepsy and complex focal onset seizures","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2022.114240","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114240"}}